- Home
- LPRO vs IPHA Comparison
LPRO vs IPHA Comparison
Compare LPRO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LPRO | IPHA |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | LPRO | IPHA |
|---|---|---|
| Price | $1.36 | $1.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $2.83 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 585.8K | 23.5K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,948,000.00 | $14,839,695.00 |
| Revenue This Year | $306.66 | $22.29 |
| Revenue Next Year | $7.97 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.70 | $1.63 |
| 52 Week High | $6.15 | $2.63 |
Technical Indicators
Market Signals| Indicator | LPRO | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 40.74 |
| Support Level | $1.62 | $1.69 |
| Resistance Level | $1.91 | $1.80 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 0.87 | 0.00 |
Price Performance
Historical ComparisonAbout LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.